Stem Cell Therapy for Parkinson's Disease Using Non-human Primate Models
Overview
Veterinary Medicine
Authors
Affiliations
Stem cell therapy (SCT) for Parkinson's disease (PD) has received considerable attention in recent years. Non-human primate (NHP) models of PD have played an instrumental role in the safety and efficacy of emerging PD therapies and facilitated the translation of initiatives for human patients. NHP models of PD include primates with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism, who are responsive to dopamine replacement therapies, similar to human PD patients. Extensive research in SCT has been conducted to better treat the progressive dopaminergic neurodegeneration that underlies PD. For effective application of SCT in PD, however, a number of basic parameters still need to be tested and optimized in NHP models, including preparation and storage of cells for engraftment, methods of transplantation, choice of target sites, and timelines for recovery. In this review, we discuss the current status of NHP models of PD in stem cell research. We also analyze the advances and remaining challenges for successful clinical translation of SCT for this persistent disease.
Circuit-specific gene therapy is knocking on the door of Parkinson's disease.
Wang Y, Yin M, Guo Z Zool Res. 2023; 44(6):1152-1153.
PMID: 37975512 PMC: 10802099. DOI: 10.24272/j.issn.2095-8137.2023.353.
hUMSCs Transplantation Regulates AMPK/NR4A1 Signaling Axis to Inhibit Ovarian Fibrosis in POI Rats.
Cui L, Bao H, Zhu W, Tang Y, Luo Q, Si Y Stem Cell Rev Rep. 2022; 19(5):1449-1465.
PMID: 36307672 DOI: 10.1007/s12015-022-10469-y.
Tello J, Williams H, Eppler R, Steinhilb M, Khanna M Front Mol Neurosci. 2022; 15:883358.
PMID: 35514431 PMC: 9063566. DOI: 10.3389/fnmol.2022.883358.
Non-human primate pluripotent stem cells for the preclinical testing of regenerative therapies.
Rodriguez-Polo I, Behr R Neural Regen Res. 2022; 17(9):1867-1874.
PMID: 35142660 PMC: 8848615. DOI: 10.4103/1673-5374.335689.
Cell motility and migration as determinants of stem cell efficacy.
Danielyan L, Schwab M, Siegel G, Brawek B, Garaschuk O, Asavapanumas N EBioMedicine. 2020; 60:102989.
PMID: 32920368 PMC: 7494685. DOI: 10.1016/j.ebiom.2020.102989.